Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.

BACKGROUND The contribution of mammalian target of rapamycin (mTOR) inhibitors to proteinuria is controversial. The aim was to analyse proteinuria in suboptimal kidney calcineurin inhibitor-(CNI) free de novo immunosuppression. METHODS All patients from our centre with donors >60 years and CNI-free treatment were included (n = 108). Patients were divided into two groups: (i) SRL group: sirolimus (SRL) + prednisone + mycophenolate mofetil (MMF) + antiCD25; (ii) MMF group: prednisone + MMF w/ or w/o antiCD25 (n = 75). Follow-up was 12 months. RESULTS Donors were slightly younger in the SRL group (68 vs 71 years; P < 0.05), receptor age (67 vs 65 years) was not significantly different. Patient survival in the MMF group was 88 vs 94% in the SRL group, however, these differences did not reach statistical significance. One-year graft survival censored for death was 83% in the MMF group and 94% in the SRL group. Acute rejection rate was 45% in the MMF and 15% in the SRL group (P < 0.01). The incidence of CNI introduction was higher in the MMF-group (35 vs 5; P < 0.05). The intention-to-treat analysis revealed significant differences of proteinuria [SRL vs MMF at 12 months: 461 (163-6988) vs 270 (53-3029) mg/day], which did not exist in the on-therapy (OT) analysis [SRL vs MMF at 12 months: 357 (199-1428) vs 279 (53-3029) mg/day]. New onset nephrotic range proteinuria seemed to occur slightly more frequently in SRL patients (3/33 vs 1/75; P = 0.049), however, all four cases occurred in a context of recurrent disease, or previous drug-independent damage or non-adherence. All of these patients were converted to CNI. CONCLUSION SRL-based compared with MMF-based treatment in kidney transplantation with advanced age donors is associated with an acceptable outcome, however, with increased proteinuria in the intention-to-treat analysis. A large subgroup of the patients in the MMF group experienced acute rejection and required conversion to CNI.

[1]  F. Diekmann,et al.  Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Wetzels,et al.  Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. , 2006, Kidney international.

[3]  D. Hricik,et al.  Differences in Proteinuria and Graft Function in De Novo Sirolimus-Based vs. Calcineurin Inhibitor-Based Immunosuppression in Live Donor Kidney Transplantation , 2006, Transplantation.

[4]  F. Diekmann,et al.  Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  C. Daniel,et al.  Mechanisms of Everolimus‐Induced Glomerulosclerosis After Glomerular Injury in the Rat , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  A. Pariente,et al.  Proteinuria Following a Switch from Calcineurin Inhibitors to Sirolimus , 2005, Transplantation.

[7]  L. Rostaing,et al.  Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  L. Butani.  Investigation of Pediatric Renal Transplant Recipients with Heavy Proteinuria after Sirolimus Rescue , 2004, Transplantation.

[9]  S. Head,et al.  De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  O. Toupance,et al.  PRELIMINARY RESULTS OF A RANDOMIZED TRIAL COMPARING SIROLIMUS (SRL) VERSUS CYCLOSPORINE (CSA) IN 150 TRANSPLANT PATIENTS RECEIVING A CADAVERIC RENAL GRAFT , 2004 .

[11]  K. Budde,et al.  Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  W. Hörl,et al.  Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  E. Morelon,et al.  Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. , 2003, Transplantation proceedings.